Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial Meeting Abstract
| Authors: | Stein, E. M.; DiNardo, C. D.; Mims, A. S.; Savona, M. R.; Pratz, K.; Stein, A. S.; Fathi, A. T.; Stone, R. M.; Pollyea, D. A.; Odenike, O.; Lowenberg, B.; Döhner, H.; Schiller, G. J.; Gupta, I. V.; Nabhan, S.; Zhang, V.; Almon, C.; Cooper, M.; Tallman, M. S. |
| Abstract Title: | Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419401373 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.726.726 |
| Notes: | Meeting Abstract: 726 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work